COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.

Autor:	Bou-Antoun S; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK., Rokadiya S; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK., Ashiru-Oredope D; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK., Demirjian A; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.; Department of Paediatric Infectious Diseases & Immunology, Evelina London Children's Hospital, London, UK.; Faculty of Life Sciences & Medicine, King's College London, London, UK., Sherwood E; Clinical and Emerging Infections (CEI), United Kingdom Health Security Agency (UKHSA), London, UK., Ellaby N; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK., Gerver S; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK., Grossi C; COVID-19 Rapid Evidence Service Public Health Advice, Guidance and Expertise (PHAGE), UK Health Security Agency, London NW9 5EQ, UK., Harman K; COVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency, London NW9 5EQ, UK., Hartman H; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK., Lochen A; Tuberculosis (TB), Acute Respiratory, Zoonoses, Emerging and Travel infections Division, UK Health Security Agency, London NW9 5EQ, UK., Ragonnet-Cronin M; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK.; MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.; Department of Ecology and Evolution, University of Chicago, Chicago, IL, USA., Squire H; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK., Sutton JM; Research and Evaluation, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.; Institute of Pharmaceutical Sciences, King's College London, London, UK., Thelwall S; COVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency, London NW9 5EQ, UK., Tree J; Research and Evaluation, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Bahar MW; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK., Stuart DI; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK., Brown CS; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK., Chand M; Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA), London, UK., Hopkins S; Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK.
Jazyk:	angličtina
Zdroj:	The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2023 Nov 23; Vol. 78 (Suppl 2), pp. ii37-ii42.
DOI:	10.1093/jac/dkad314
Abstrakt:	The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics. (© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu